JAMA Dermatology

<jats:sec id="ab-drv250004-4"><jats:title>Importance</jats:title><jats:p>Patient and caregiver values and preferences should inform clinical management. An update to the American Academy of Allergy, Asthma &amp;amp;amp; Immunology/American College of Allergy, Asthma and Immunology’s Joint Task Force on Practice Parameters guidelines on chronic urticaria (CU) plans to incorporate them; however, a systematic review of evidence on the values and preferences of patients with CU and their caregivers has not been previously available.</jats:p></jats:sec><jats:sec id="ab-drv250004-5"><jats:title>Objective</jats:title><jats:p>To synthesize patient and caregiver values and preferences regarding CU treatment options.</jats:p></jats:sec><jats:sec id="ab-drv250004-6"><jats:title>Evidence Review</jats:title><jats:p>A systematic search was conducted of  MEDLINE, Embase, PsycINFO, and CINAHL databases, from inception to May 15, 2025, for studies addressing patient and/or caregiver values and preferences for CU management. Paired reviewers independently screened studies, extracted data, and assessed risk of bias. Thematic and inductive content analysis was used to qualitatively synthesize findings and certainty of evidence was rated per the Grading of Recommendations Assessment, Development and Evaluation−Confidence in the Evidence from Reviews of Qualitative Research approach.</jats:p></jats:sec><jats:sec id="ab-drv250004-7"><jats:title>Findings</jats:title><jats:p>The search resulted in 18 studies addressing the values and preferences among 28 497 participants. Moderate certainty evidence showed that patients were likely to place a high value on rapid improvement (eg, 2 days to 2 weeks) of disease signs and symptoms, long-term effectiveness, and treatments that were easy to prepare, use, and self-manage—oral or topical treatments were favored over injections, with the least favored being infusions. Low certainty evidence suggested that patients accepted minor feasibility burdens for rapid and sustained symptom relief but prioritized safety and tolerability as the risk or severity of adverse effects (eg, kidney injury, vomiting) increased.</jats:p></jats:sec><jats:sec id="ab-drv250004-8"><jats:title>Conclusions and Relevance</jats:title><jats:p>This systematic review suggests that patients with CU place high value on immediate and sustained hive, itch, and swelling relief, particularly long-term symptom-free periods, but may shift to prioritizing avoiding harms and burdens as the risk and severity of adverse effects increases. These findings may serve as a resource to improve the trustworthiness of recommendations and inform future CU management and research.</jats:p></jats:sec>

Chronic urticaria and angioedema: masqueraders and misdiagnoses.

J Allergy Clin Immunol Pract

The diagnosis and management of acute and chronic urticaria: 2014 update.

J Allergy Clin Immunol

Chronic Urticaria.

N Engl J Med

Chronic spontaneous urticaria guidelines: what is new?

Urticaria and angioedema across the ages.

Translating evidence to optimize patient care using GRADE.

Trustworthy patient-centered guidelines: insights from atopic dermatitis and a proposal for the future.

Values and preferences of patients and caregivers regarding treatment of atopic dermatitis (eczema): a systematic review.

JAMA Dermatol

Using patient values and preferences to inform the importance of health outcomes in practice guideline development following the GRADE approach.

Health Qual Life Outcomes

The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria.

Allergy

Topical corticosteroids for hives and itch (urticaria): systematic review and Bayesian meta-analysis of randomized trials.

Ann Allergy Asthma Immunol

Leukotriene receptor antagonists as add-on therapy to antihistamines for urticaria: systematic review and meta-analysis of randomized clinical trials.

Efficacy and safety of systemic corticosteroids for urticaria: a systematic review and meta-analysis of randomized clinical trials.

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.

Extracting data from figures with software was faster, with higher interrater reliability than manual extraction.

J Clin Epidemiol

Values and preferences towards medical cannabis among people living with chronic pain: a mixed-methods systematic review.

BMJ Open

How do patients’ values influence heart failure self-care decision-making?: A mixed-methods systematic review.

Int J Nurs Stud

Health-related values and preferences regarding meat consumption: a mixed-methods systematic review.

Ann Intern Med

A classification of response scale characteristics that affect data quality: a literature review.

Qual Quant

Patient values and preferences on valve replacement for aortic stenosis: a systematic review.

Heart

A framework for practical issues was developed to inform shared decision-making tools and clinical guidelines.

Needs and preferences of patients regarding atopic dermatitis care in the era of new therapeutic options: a qualitative study.

Arch Dermatol Res

Methods for the thematic synthesis of qualitative research in systematic reviews.

BMC Med Res Methodol

Parents and GPs’ understandings and beliefs about food allergy testing in children with eczema: qualitative interview study within the Trial of Eczema allergy Screening Tests (TEST) feasibility trial.

GRADE Guidelines: 19. Assessing the certainty of evidence in the importance of outcomes or values and preferences-Risk of bias and indirectness.

Applying GRADE-CERQual to qualitative evidence synthesis findings-paper 7: understanding the potential impacts of dissemination bias.

Implement Sci

Applying GRADE-CERQual to qualitative evidence synthesis findings-paper 4: how to assess coherence.

Applying GRADE-CERQual to qualitative evidence synthesis findings-paper 5: how to assess adequacy of data.

Applying GRADE-CERQual to qualitative evidence synthesis findings-paper 2: how to make an overall CERQual assessment of confidence and create a summary of qualitative findings table.

Applying GRADE-CERQual to qualitative evidence synthesis findings: introduction to the series.

Applying GRADE-CERQual to qualitative evidence synthesis findings-paper 3: how to assess methodological limitations.

Applying GRADE-CERQual to qualitative evidence synthesis findings-paper 6: how to assess relevance of the data.

Do traditional beliefs about urticaria affect patient satisfaction in South India? – A knowledge, attitude and practices survey.

J Pak Assoc Dermatol

Educational level and job status are the most important factors affecting compliance with oral antihistamine therapy for patients with chronic urticaria.

J Dermatolog Treat

Quantifying patient preferences for treatments for refractory chronic spontaneous urticaria.

An open-label, multicentre study of levocetirizine for the treatment of allergic rhinitis and urticaria in Taiwanese patients.

Chin J Physiol

Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective.

World Allergy Organ J

ATTENTUS, a German online survey of patients with chronic urticaria highlighting the burden of disease, unmet needs and real-life clinical practice.

Br J Dermatol

Chronic urticaria: a patient survey on quality-of-life, treatment usage and doctor-patient relation.

Treatment satisfaction in chronic urticaria during guideline-based therapy.

J Dtsch Dermatol Ges

Characteristics and determinants of patient burden and needs in the treatment of chronic spontaneous urticaria.

Eur J Dermatol

Use of, satisfaction with, and willingness to switch prescription and over-the-counter treatments for chronic urticaria: an online survey.

Patient

Patients with Chronic Urticaria Remain Largely Undertreated: results from the DERMLINE Online Survey.

Dermatol Ther (Heidelb)

Psychological well-being, quality of life and patient satisfaction among adults with chronic spontaneous urticaria in a multi-ethnic Asian population.

Psychol Health Med

Autoadministração de omalizumab na urticária crónica espontânea – Estudo observacional num centro UCARE.

Rev Port Imunoalergol

Assessing preferences of patients with chronic spontaneous urticaria for injectable treatment profiles.

Patient experiences of using Chinese herbal medicine for psoriasis vulgaris and chronic urticaria: a qualitative study.

Multicentre experience of home omalizumab treatment for chronic spontaneous urticaria.

Eur J Hosp Pharm

Perspectives on living with chronic spontaneous urticaria: from onset through diagnosis and disease management in the US.

Acta Derm Venereol

Understanding the impact of chronic spontaneous urticaria (CSU) and what is most important to patients 2014; results from qualitative patient interviews.

Value Health

Core GRADE 1: overview of the Core GRADE approach.

Urticaria voices: real-world experience of patients living with chronic spontaneous urticaria.

Online education with the patient voice highlights continuous gaps in care and needs for therapeutic options for chronic spontaneous urticaria (CSU) management.

A Patient charter for chronic urticaria.

Adv Ther

Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations.

Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria.

Long-term omalizumab in elderly patients with chronic urticaria: is it a safe therapy?

Int Arch Allergy Immunol

Comparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic urticaria: Systematic review and network meta-analysis.

Multinational drug survival study of omalizumab in patients with chronic urticaria and potential predictors for discontinuation.

Practical applications of methods to incorporate patient preferences into medical decision models: a scoping review.

BMC Med Inform Decis Mak

Patient and caregiver values and preferences should inform clinical management. An update to the American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology's Joint Task Force on Practice Parameters guidelines on chronic urticaria (CU) plans to incorporate them; however, a systematic review of evidence on the values and preferences of patients with CU and their caregivers has not been previously available.
To synthesize patient and caregiver values and preferences regarding CU treatment options.
A systematic search was conducted of MEDLINE, Embase, PsycINFO, and CINAHL databases, from inception to May 15, 2025, for studies addressing patient and/or caregiver values and preferences for CU management. Paired reviewers independently screened studies, extracted data, and assessed risk of bias. Thematic and inductive content analysis was used to qualitatively synthesize findings and certainty of evidence was rated per the Grading of Recommendations Assessment, Development and Evaluation-Confidence in the Evidence from Reviews of Qualitative Research approach.
The search resulted in 18 studies addressing the values and preferences among 28 497 participants. Moderate certainty evidence showed that patients were likely to place a high value on rapid improvement (eg, 2 days to 2 weeks) of disease signs and symptoms, long-term effectiveness, and treatments that were easy to prepare, use, and self-manage-oral or topical treatments were favored over injections, with the least favored being infusions. Low certainty evidence suggested that patients accepted minor feasibility burdens for rapid and sustained symptom relief but prioritized safety and tolerability as the risk or severity of adverse effects (eg, kidney injury, vomiting) increased.
This systematic review suggests that patients with CU place high value on immediate and sustained hive, itch, and swelling relief, particularly long-term symptom-free periods, but may shift to prioritizing avoiding harms and burdens as the risk and severity of adverse effects increases. These findings may serve as a resource to improve the trustworthiness of recommendations and inform future CU management and research.

Patient Values and Preferences in Chronic Urticaria Treatment: A Systematic Review.

Patient Values and Preferences in Chronic Urticaria Treatment

The Journal of Dermatology

<jats:title>Abstract</jats:title><jats:p>The long‐term complications of coronavirus disease 2019 (COVID‐19) continue to cause global concern. This study aimed to estimate the incidence and risk of chronic urticaria, vitiligo, alopecia areata, and herpes zoster following COVID‐19 infection. Only participants confirmed by real‐time reverse transcription‐polymerase chain reaction tests to have COVID‐19 were enrolled in the COVID‐19 group. The matched cohort without COVID‐19 was enrolled randomly at a ratio of 1:1. The incidence and risk of chronic urticaria, vitiligo, alopecia areata, and herpes zoster were assessed in both groups using univariable and multivariable Cox proportional hazard analyses. A total of 4 976 589 COVID‐19 patients (9.58% of the total population of South Korea) and an equivalent number of matched non‐infected control subjects were analyzed. Chronic urticaria, vitiligo, alopecia areata, and herpes zoster manifested at higher rates within the COVID‐19 cohort, even after multivariable adjustment for potential confounders. COVID‐19 may increase the risk of developing chronic urticaria, vitiligo, alopecia areata, and herpes zoster.</jats:p>

publication_history

received

accepted

published

National Research Foundation of Korea

Data resource profile: the national health information database of the National Health Insurance Service in South Korea

Int J Epidemiol

Vitiligo following COVID‐19 vaccination and primary infection: a case report and systematic review

Cureus

The long-term complications of coronavirus disease 2019 (COVID-19) continue to cause global concern. This study aimed to estimate the incidence and risk of chronic urticaria, vitiligo, alopecia areata, and herpes zoster following COVID-19 infection. Only participants confirmed by real-time reverse transcription-polymerase chain reaction tests to have COVID-19 were enrolled in the COVID-19 group. The matched cohort without COVID-19 was enrolled randomly at a ratio of 1:1. The incidence and risk of chronic urticaria, vitiligo, alopecia areata, and herpes zoster were assessed in both groups using univariable and multivariable Cox proportional hazard analyses. A total of 4 976 589 COVID-19 patients (9.58% of the total population of South Korea) and an equivalent number of matched non-infected control subjects were analyzed. Chronic urticaria, vitiligo, alopecia areata, and herpes zoster manifested at higher rates within the COVID-19 cohort, even after multivariable adjustment for potential confounders. COVID-19 may increase the risk of developing chronic urticaria, vitiligo, alopecia areata, and herpes zoster.

Epidemiological insights into chronic urticaria, vitiligo, alopecia areata, and herpes zoster following COVID-19 infection: A nationwide population-based study.

Epidemiological insights into chronic urticaria, vitiligo, alopecia areata, and herpes zoster following <scp>COVID</scp>‐19 infection: A nationwide population‐based study

Papers